TST and prostate carcinoma: The first objectives of this research was to verify the concept that amygdalin triggers growth inhibition in human prostate cancer cell line PC3 cells in vivo and to analyze its metabolic enzymes rhodanese and betaglucosidase as a potential adjunct to the existing prostate cancer therapy regimen (Figure 5).